SWAV Stock Recent News

After reaching an important support level, Shockwave Medical (SWAV) could be a good stock pick from a technical perspective. SWAV surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.

SANTA CLARA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the third quarter 2023 after market close on Monday, November 6, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

SANTA CLARA, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, announced today that the company will be participating in two upcoming investor conferences:

Shockwave Medical Inc. is a medical device developer focusing on calcified cardiovascular disease treatments, with a promising market opportunity. SWAV recently completed the acquisition of Neovasc Inc., positioning itself to address refractory angina and tap into a large market share. SWAV has strong margins and financial position, but its current valuation is considered overpriced, making it a hold rather than a buy.

Shockwave Medical's (SWAV) second-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

Shockwave Medical's Q2 results exceeded revenue expectations but fell short on earnings. The bottom-line shortfall came amid acquisition expenses and headcount expansion to support growth.

Shockwave Medical (SWAV) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.68 per share a year ago.

SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.